Search

Your search keyword '"Bojesen, Stig Egil"' showing total 150 results
Start Over Author "Bojesen, Stig Egil"
150 results on '"Bojesen, Stig Egil"'

10. Incidental lymphopenia and mortality: a prospective cohort study

Author

Warny, Marie, Helby, Jens, Nordestgaard, Borge Granne, Birgens, Henrik, and Bojesen, Stig Egil

Subjects
Mortality -- Denmark -- Analysis, Lymphocytes -- Analysis -- Health aspects, Lymphocytopenia -- Analysis -- Health aspects, Respiratory tract diseases -- Analysis -- Health aspects, Communicable diseases -- Analysis -- Health aspects, Lung diseases, Cancer, Health
Abstract

BACKGROUND: It is unknown if incidental lymphopenia detected in the general population is associated with higher all-cause and cause-specific mortality. We aimed to identify the associations between lymphopenia and all-cause and cause specific mortality. METHODS: In a prospective cohort study, we examined and followed participants enrolled in the Copenhagen General Population Study between November 2003 and April 2015. In our analysis, we modelled risks using Cox proportional hazards regression for 3 groups: participants with a lymphocyte count below the 2.5th percentile; those with a lymphocyte count at or between the 2.5th and 97.5th percentiles (reference category); and those with a lymphocyte count above the 97.5th percentile. RESULTS: The cohort included 108135 participants with a median age of 68 years. During a median follow-up of 9 (interquartile range [IQR] 0-14) years, 10 372 participants died. We found that participants with lymphopenia (lymphocyte count < 1.1 x [10.sup.9]/L) compared with those with a lymphocyte count in the reference range (1.1-3.7 x [10.sup.9]/L) had higher mortality with multivariable adjusted hazard ratios (HRs) of 1.63 (95% confidence interval [CI] 1.51-1.76) for all causes, 1.67 (95% CI 1.42-1.97) for nonhematologic cancers, 2.79 (95% CI 1.82-4.28) for hematologic cancers, 1.88 (95% CI 1.61-2.20) for cardiovascular diseases, 1.88 (95% CI 1.55-2.29) for respiratory diseases, 1.86 (95% CI 1.53-2.25) for infectious diseases, and 1.50 (95% CI 1.19-1.88) for other causes. For all-cause mortality, the highest absolute 2-year risks of death were observed in women (61%) and men (75%) who smoked and were aged 80 years or older with lymphocyte counts less than 0.5 x [10.sup.9]/L. Participants with a lymphocyte count higher than the reference category had increased mortality (adjusted HR 1.17, 95% CI 1.04-1.31). INTERPRETATION: We found that lymphopenia was associated with an increased risk of all-cause and causespecific mortality., Lymphopenia in an otherwise healthy person is typically discovered when doing routine blood counts. In Denmark, patients with incidental lymphopenia are usually not referred for further examination because the mortality [...]

Published
2020
Full Text
View/download PDF

14. Diminishing benefits of urban living for children and adolescents’ growth and development

Author

Mishra, Anu, Zhou, Bin, Rodriguez-Martinez, Andrea, Bixby, Honor, Baker, Jennifer Lyn, Afzal, Shoaib, Allin, Kristine, Andersen, Lars Bo, Ängquist, Lars, Jørgensen, Maja Bæksgaard, Bjerregaard, Peter, Bojesen, Stig Egil, Christensen, Kaare, Damsgaard, Camilla Trab, Dantoft, Thomas M, Eliasen, Marie, Eriksen, Louise, Halkjær, Jytte, Giwercman, Aleksander, Jørgensen, Torben, Kristensen, Peter Lund, Lind, Lars, Linneberg, Allan, Madsen, Anja Lykke, Michaelsen, Kim F., Møllehave, Line Tang, Mortensen, Erik Lykke, Nordestgaard, Børge, Osler, Merete, Overvad, Kim, Schmidt, Ida Maria, Schnohr, Peter, Schramm, Stine, Sodemann, Morten, Sørensen, Thorkild I.A., Tjønneland, Anne, Tolstrup, Janne S, and Wang, Qian

Subjects
Urban living, Health, Well-being, Faculty of Science, Growth, Development, Adolescents, Children
Abstract

Optimal growth and development in childhood and adolescence is crucial for lifelong health and well-being1–6. Here we used data from 2,325 population-based studies, with measurements of height and weight from 71 million participants, to report the height and body-mass index (BMI) of children and adolescents aged 5–19 years on the basis of rural and urban place of residence in 200 countries and territories from 1990 to 2020. In 1990, children and adolescents residing in cities were taller than their rural counterparts in all but a few high-income countries. By 2020, the urban height advantage became smaller in most countries, and in many high-income western countries it reversed into a small urban-based disadvantage. The exception was for boys in most countries in sub-Saharan Africa and in some countries in Oceania, south Asia and the region of central Asia, Middle East and north Africa. In these countries, successive cohorts of boys from rural places either did not gain height or possibly became shorter, and hence fell further behind their urban peers. The difference between the age-standardized mean BMI of children in urban and rural areas was –2 in the vast majority of countries. Within this small range, BMI increased slightly more in cities than in rural areas, except in south Asia, sub-Saharan Africa and some countries in central and eastern Europe. Our results show that in much of the world, the growth and developmental advantages of living in cities have diminished in the twenty-first century, whereas in much of sub-Saharan Africa they have amplified.

Published
2023

19. Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score

Author

Åberg, Fredrik, primary, Luukkonen, Panu K., additional, But, Anna, additional, Salomaa, Veikko, additional, Britton, Annie, additional, Petersen, Kasper Meidahl, additional, Bojesen, Stig Egil, additional, Balling, Mie, additional, Nordestgaard, Børge G., additional, Puukka, Pauli, additional, Männistö, Satu, additional, Lundqvist, Annamari, additional, Perola, Markus, additional, Jula, Antti, additional, and Färkkilä, Martti, additional

Published
2022
Full Text
View/download PDF

20. Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity

Author

Ferreiro-Iglesias, Aida, Lesseur, Corina, McKay, James, Hung, Rayjean J., Han, Younghun, Zong, Xuchen, Christiani, David, Johansson, Mattias, Xiao, Xiangjun, Li, Yafang, Qian, David C., Ji, Xuemei, Liu, Geoffrey, Caporaso, Neil, Scelo, Ghislaine, Zaridze, David, Mukeriya, Anush, Kontic, Milica, Ognjanovic, Simona, Lissowska, Jolanta, Szołkowska, Małgorzata, Swiatkowska, Beata, Janout, Vladimir, Holcatova, Ivana, Bolca, Ciprian, Savic, Milan, Ognjanovic, Miodrag, Bojesen, Stig Egil, Wu, Xifeng, Albanes, Demetrios, Aldrich, Melinda C., Tardon, Adonina, Fernandez-Somoano, Ana, Fernandez-Tardon, Guillermo, Le Marchand, Loic, Rennert, Gadi, Chen, Chu, Doherty, Jennifer, Goodman, Gary, Bickeböller, Heike, Wichmann, H-Erich, Risch, Angela, Rosenberger, Albert, Shen, Hongbing, Dai, Juncheng, Field, John K., Davies, Michael, Woll, Penella, Teare, M. Dawn, Kiemeney, Lambertus A., van der Heijden, Erik H. F. M., Yuan, Jian-Min, Hong, Yun-Chul, Haugen, Aage, Zienolddiny, Shanbeh, Lam, Stephen, Tsao, Ming-Sound, Johansson, Mikael, Grankvist, Kjell, Schabath, Matthew B., Andrew, Angeline, Duell, Eric, Melander, Olle, Brunnström, Hans, Lazarus, Philip, Arnold, Susanne, Slone, Stacey, Byun, Jinyoung, Kamal, Ahsan, Zhu, Dakai, Landi, Maria Teresa, Amos, Christopher I., and Brennan, Paul

Published
2018
Full Text
View/download PDF

21. Associations of a breast cancer polygenic risk score with tumor characteristics and survival.

Author

Lopes Cardozo, Josephine, primary, Andrulis, Irene L., additional, Peter, Devilee, additional, Dörk, Thilo, additional, Drukker, Caroline, additional, Fasching, Peter A., additional, Hooning, Maartje J., additional, Keeman, Renske, additional, Nevanlinna, Heli, additional, Rutgers, Emiel J., additional, van 't Veer, Laura, additional, Hall, Per, additional, Bojesen, Stig Egil, additional, Douglas, Easton, additional, Eccles, Diana, additional, Pharoah, Paul, additional, and Schmidt, Marjanka, additional

Published
2022
Full Text
View/download PDF

23. BMC Bioinformatics / I am hiQ—a novel pair of accuracy indices for imputed genotypes

Author

Rosenberger, Albert, Tozzi, Viola, Bickeböller, Heike, Hung, Rayjean J., Christiani, David C., Caporaso, Neil E., Albanes, Demetrios, Landi, Maria Teresa, Liu, Geoffrey, Bojesen, Stig Egil, Marchand, Loic Le, Aldrich, Melinda C., Tardon, Adonina, Fernández-Tardón, Guillermo, Rennert, Gad, Field, John, Davies, Mike, Liloglou, Triantafillos, Kiemeney, Lambertus A., Lazarus, Philip, Haugen, Aage, Zienolddiny, Shanbeh, Lam, Stephen, Schabath, Matthew B., Andrew, Angeline S., Duell, Eric J., Arnold, Susanne Margaretha, Brunnström, Hans, Melander, Olle, Chen, Chu, Doherty, Jennifer A., Teare, Marion Dawn, Cox, Angela, Woll, Penella J., Risch, Angela, Muley, Thomas R., Vejdemo-Johansson, Mikael, Brennan, Paul, Shete, Sanjay S., and Amos, Christopher I.

Subjects
Genotype imputation, High-throughput genotyping, Accuracy measures, GWAS
Abstract

Background: Imputation of untyped markers is a standard tool in genome-wide association studies to close the gap between directly genotyped and other known DNA variants. However, high accuracy with which genotypes are imputed is fundamental. Several accuracy measures have been proposed and some are implemented in imputation software, unfortunately diversely across platforms. In the present paper, we introduce Iam hiQ, an independent pair of accuracy measures that can be applied to dosage files, the output of all imputation software. Iam (imputation accuracy measure) quantifies the average amount of individual-specific versus population-specific genotype information in a linear manner. hiQ (heterogeneity in quantities of dosages) addresses the inter-individual heterogeneity between dosages of a marker across the sample at hand. Results: Applying both measures to a large case–control sample of the International Lung Cancer Consortium (ILCCO), comprising 27,065 individuals, we found meaningful thresholds for Iam and hiQ suitable to classify markers of poor accuracy. We demonstrate how Manhattan-like plots and moving averages of Iam and hiQ can be useful to identify regions enriched with less accurate imputed markers, whereas these regions would by missed when applying the accuracy measure info (implemented in IMPUTE2). Conclusion: We recommend using Iam hiQ additional to other accuracy scores for variant filtering before stepping into the analysis of imputed GWAS data.

Published
2022

25. Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study

Author

Warny, Marie, Helby, Jens, Nordestgaard, Børge Grønne, Birgens, Henrik, and Bojesen, Stig Egil

Subjects
Lymphocytopenia -- Complications and side effects, Cross infection -- Risk factors -- Patient outcomes, Neutropenia -- Complications and side effects, Death, Lymphocytes, Pneumonia, Medical research, C-reactive protein, Endocarditis, Diarrhea, Emigration and immigration, Urinary tract infections, Skin, Drinking (Alcoholic beverages), Infection, Autoimmune diseases, Comorbidity, Biological sciences
Abstract

Background Neutropenia increases the risk of infection, but it is unknown if this also applies to lymphopenia. We therefore tested the hypotheses that lymphopenia is associated with increased risk of infection and infection-related death in the general population. Methods and findings Of the invited 220,424 individuals, 99,191 attended examination. We analyzed 98,344 individuals from the Copenhagen General Population Study (Denmark), examined from November 25, 2003, to July 9, 2013, and with available blood lymphocyte count at date of examination. During a median of 6 years of follow-up, they developed 8,401 infections and experienced 1,045 infection-related deaths. Due to the completeness of the Danish civil and health registries, none of the 98,344 individuals were lost to follow-up, and those emigrating (n = 385) or dying (n = 5,636) had their follow-up truncated at the day of emigration or death. At date of examination, mean age was 58 years, and 44,181 (44.9%) were men. Individuals with lymphopenia (lymphocyte count < 1.1 x 10.sup.9 /l, n = 2,352) compared to those with lymphocytes in the reference range (1.1-3.7 x 10.sup.9 /l, n = 93,538) had multivariable-adjusted hazard ratios of 1.41 (95% CI 1.28-1.56) for any infection, 1.31 (1.14-1.52) for pneumonia, 1.44 (1.15-1.79) for skin infection, 1.26 (1.02-1.56) for urinary tract infection, 1.51 (1.21-1.89) for sepsis, 1.38 (1.01-1.88) for diarrheal disease, 2.15 (1.16-3.98) for endocarditis, and 2.26 (1.21-4.24) for other infections. The corresponding hazard ratio for infection-related death was 1.70 (95% CI 1.37-2.10). Analyses were adjusted for age, sex, smoking status, cumulative smoking, alcohol intake, body mass index, plasma C-reactive protein, blood neutrophil count, recent infection, Charlson comorbidity index, autoimmune diseases, medication use, and immunodeficiency/hematologic disease. The findings were robust in all stratified analyses and also when including only events later than 2 years after first examination. However, due to the observational design, the study cannot address questions of causality, and our analyses might theoretically have been affected by residual confounding and reverse causation. In principle, fluctuating lymphocyte counts over time might also have influenced analyses, but lymphocyte counts in 5,181 individuals measured 10 years after first examination showed a regression dilution ratio of 0.68. Conclusions Lymphopenia was associated with increased risk of hospitalization with infection and increased risk of infection-related death in the general population. Notably, causality cannot be deduced from our data., Author(s): Marie Warny 1,2, Jens Helby 3,4, Børge Grønne Nordestgaard 2,3,4, Henrik Birgens 1,2, Stig Egil Bojesen 2,3,4,* Introduction Neutropenia (neutrophil count < 0.5 x 10[sup.9] /l) is associated with [...]

Published
2018
Full Text
View/download PDF

26. Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses

Author

Drechsler, Christiane, Bolland, Mark J., Reid, Ian, Willeit, Johann, Schett, Georg, Santer, Peter, Sofat, Reecha, Taylor, Julie, Dale, Caroline, Prince, Richard L., Ben-Shlomo, Yoav, Gallacher, John, Jensen, Gorm B., Frikke-Schmidt, Ruth, Bojesen, Stig Egil, Benn, Marianne, Wulff, Anders B., Krogh, Signe V., Schierbeck, Louise Lind, Kaptoge, Stephen, Wareham, Nicholas, Schöttker, Ben, Zhu, Anna, Holleczek, Bernd, Dennison, Elaine, Jameson, Karen, Schleithoff, Stefanie Schulze, Frisch, Sabine, Linneberg, Allan, Skaaby, Tea, Kårhus, Line Lund, de Jongh, Renate T., Visser, Marjolein, Dobnig, Harald, Robinson-Cohen, Cassianne, Siscovick, David S., Kestenbaum, Bryan R., McConnachie, Alex, Sattar, Naveed, Morrison, David, Lundqvist, Annamari, Cawthon, Peggy M., Albertorio, Juan R., Jukema, J Wouter, Trompet, Stella, Kearney, Patricia, Dörr, Marcus, Völzke, Henry, Nauck, Matthias, Rossing, Peter, Persson, Frederik, Marniemi, Jukka, Vazquez, Victoria, Sundström, Johan, Risérus, Ulf, Michaëlsson, Karl, Emberson, Jonathan, Leon, David, and Kivimäki, Mika

Abstract

Background:\ud Randomised trials of vitamin D supplementation for cardiovascular disease and all-cause mortality have generally reported null findings. However, generalisability of results to individuals with low vitamin D status is unclear. We aimed to characterise dose-response relationships between 25-hydroxyvitamin D (25[OH]D) concentrations and risk of coronary heart disease, stroke, and all-cause mortality in observational and Mendelian randomisation frameworks.\ud \ud Methods:\ud Observational analyses were undertaken using data from 33 prospective studies comprising 500 962 individuals with no known history of coronary heart disease or stroke at baseline. Mendelian randomisation analyses were performed in four population-based cohort studies (UK Biobank, EPIC-CVD, and two Copenhagen population-based studies) comprising 386 406 middle-aged individuals of European ancestries, including 33 546 people who developed coronary heart disease, 18 166 people who had a stroke, and 27 885 people who died. Primary outcomes were coronary heart disease, defined as fatal ischaemic heart disease (International Classification of Diseases 10th revision code I20-I25) or non-fatal myocardial infarction (I21-I23); stroke, defined as any cerebrovascular disease (I60-I69); and all-cause mortality.\ud \ud Findings:\ud Observational analyses suggested inverse associations between incident coronary heart disease, stroke, and all-cause mortality outcomes with 25(OH)D concentration at low 25(OH)D concentrations. In population-wide genetic analyses, there were no associations of genetically-predicted 25(OH)D with coronary heart disease, stroke, or all-cause mortality. However, for the participants with vitamin D deficiency (25[OH]D concentration

Published
2021

29. Early detection of lung cancer using cfDNA fragmentation.

Author

Mathios, Dimitrios, primary, Johansen, Jakob Sidenius, additional, Cristiano, Stephen, additional, Medina, Jamie, additional, Phallen, Jillian, additional, Richter Larsen, Klaus, additional, Bruhm, Daniel, additional, Niknafs, Noushin, additional, Nielsen, Hans J., additional, Meijer, Gerrit A., additional, Andersen, Claus Lindbjerg, additional, Bojesen, Stig Egil, additional, Scharpf, Robert, additional, and Velculescu, Victor E., additional

Published
2021
Full Text
View/download PDF

32. Additional file 1 of Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals

Author

Pedersen, Kasper Mønsted, Çolak, Yunus, Bojesen, Stig Egil, and Nordestgaard, Børge Grønne

Subjects
lipids (amino acids, peptides, and proteins)
Abstract

Additional file 1: Table S1. Baseline characteristics of individuals in the Copenhagen General Population Study according to HDL cholesterol levels. Table S2. Baseline characteristics of individuals in the Copenhagen General Population Study according to apolipoprotein A1 levels. Table S3. Baseline characteristics of individuals in the Copenhagen City Heart Study according to HDL cholesterol levels. Table S4. Baseline characteristics of individuals in the Copenhagen City Heart Study according to apolipoprotein A1 levels. Figure S1. Association of HDL cholesterol levels with risk of gynecological, urological, gastrointestinal, prostate, malignant melanoma, and other cancer in individuals from the Copenhagen General Population Study. Figure S2. Association of apolipoprotein A1 levels with risk of gynecological, urological, gastrointestinal, prostate, malignant melanoma, and other cancer in individuals from the Copenhagen General Population Study. Figure S3a and S3b. Association of HDL cholesterol levels with risk of 27 specific cancer types in individuals from the Copenhagen General Population Study. Figure S4a and S4b. Association of apolipoprotein A1 levels with risk of 27 specific cancer types in individuals from the Copenhagen General Population Study. Figure S5. Association of HDL cholesterol and apolipoprotein A1 levels with risk of hematological, breast, and respiratory cancer in individuals from the Copenhagen City Heart Study. Figure S6. Association of HDL cholesterol and apolipoprotein A1 levels with risk of any cancer in individuals from the Copenhagen General Population Study according to sex. Figure S7. Association of HDL cholesterol levels with risk of eight major cancer forms in women from the Copenhagen General Population Study. Figure S8. Association of HDL cholesterol levels with risk of seven major cancer forms in men from the Copenhagen General Population Study. Figure S9. Association of low versus high HDL cholesterol levels with risk of any cancer in individuals from the Copenhagen General Population Study according to covariates. Figure S10. Association of HDL cholesterol and apolipoprotein A1 levels with risk of any cancer and nine major cancer forms in individuals from the Copenhagen General Population Study with all-cause mortality and emigration as competing events. Figure S11. Association of HDL cholesterol and apolipoprotein A1 levels with risk of any cancer in individuals from the Copenhagen General Population Study excluding individuals with 1, 2, and 3 years of follow-up. Figure S12. Association of HDL cholesterol levels with risk of hematological, breast, and respiratory cancer in individuals from the Copenhagen General Population Study excluding individuals with 1, 2, and 3 years of follow-up. Figure S13. Association of apolipoprotein A1 levels with risk of hematological, breast, and respiratory cancer in individuals from the Copenhagen General Population Study excluding individuals with 1, 2, and 3 years of follow-up. Figure S14. HDL cholesterol and apolipoprotein A1 levels adjusted risk of any cancer in individuals from the Copenhagen General Population Study.

Published
2020
Full Text
View/download PDF

34. Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer

Author

Kachuri, Linda, primary, Helby, Jens, additional, Bojesen, Stig Egil, additional, Christiani, David C., additional, Su, Li, additional, Wu, Xifeng, additional, Tardón, Adonina, additional, Fernández-Tardón, Guillermo, additional, Field, John K., additional, Davies, Michael P., additional, Chen, Chu, additional, Goodman, Gary E., additional, Shepherd, Frances A., additional, Leighl, Natasha B., additional, Tsao, Ming S., additional, Brhane, Yonathan, additional, Brown, M. Catherine, additional, Boyd, Kevin, additional, Shepshelovich, Daniel, additional, Sun, Lei, additional, Amos, Christopher I., additional, Liu, Geoffrey, additional, and Hung, Rayjean J., additional

Published
2019
Full Text
View/download PDF

38. Secular trends in smoking in relation to prevalent and incident smoking-related disease: A prospective population-based study.

Author

Tonnesen, Philip, Marott, Jacob L., Nordestgaard, Børge, Bojesen, Stig Egil, and Lange, Peter

Abstract

INTRODUCTION We examined changes in smoking habits in the general population according to prevalence and incidence of chronic diseases affected by smoking. METHODS We included 12283 individuals enrolled from 2003 in the Copenhagen General Population Study and re-examined from 2014. Participants were classified as either healthy or suffering from chronic obstructive pulmonary disease (COPD), asthma, diabetes mellitus, heart disease or stroke. RESULTS At entry, smoking prevalence was 15.4% in healthy participants, 29.8% with COPD, 15.8% with asthma, 21.7 % with diabetes mellitus, 17.2 % with ischemic heart disease/heart failure and 18.6% in participants with previous stroke. Smoking prevalence declined during the 10 years of observation. Among healthy subjects who developed one of the above mentioned diseases during follow-up, those who developed COPD had the highest initial smoking prevalence (51.5%). Quit rates were highest in those who developed asthma resulting in smoking prevalence of 8.2% versus 27.7% in COPD. After adjustment for age, smoking severity and genotype previously associated with heavy smoking (CHRNA3 rs1051730 AA), significant predictors of quitting were new diagnosis of ischemic heart disease/heart failure (OR=2.33, 95 % CI: 1.61–3.42), new diagnosis of asthma (OR=1.84, 95% CI: 1.18–2.90) and low number of pack-years. CONCLUSIONS Individuals with prevalent smoking related diseases continued to smoke more than healthy individuals. Incident heart disease and asthma, but not incident COPD, stroke or diabetes were associated with a higher chance of quitting. Special focus on smokers with COPD, asthma, diabetes, stroke and ischemic heart disease/heart failure is warranted to decrease smoking prevalence in these groups. Smokers with a new diagnosis of diabetes, stroke and COPD need special smoking cessation support. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

39. Mendelian Randomization and mediation analysis of leukocyte telomere length and risk of lung and head and neck cancers

Author

Kachuri, Linda, primary, Saarela, Olli, primary, Bojesen, Stig Egil, primary, Davey Smith, George, primary, Liu, Geoffrey, primary, Landi, Maria Teresa, primary, Caporaso, Neil E, primary, Christiani, David C, primary, Johansson, Mattias, primary, Panico, Salvatore, primary, Overvad, Kim, primary, Trichopoulou, Antonia, primary, Vineis, Paolo, primary, Scelo, Ghislaine, primary, Zaridze, David, primary, Wu, Xifeng, primary, Albanes, Demetrius, primary, Diergaarde, Brenda, primary, Lagiou, Pagona, primary, Macfarlane, Gary J, primary, Aldrich, Melinda C, primary, Tardón, Adonina, primary, Rennert, Gad, primary, Olshan, Andrew F, primary, Weissler, Mark C, primary, Chen, Chu, primary, Goodman, Gary E, primary, Doherty, Jennifer A, primary, Ness, Andrew R, primary, Bickeböller, Heike, primary, Wichmann, H-Erich, primary, Risch, Angela, primary, Field, John K, primary, Teare, M Dawn, primary, Kiemeney, Lambertus A, primary, van der Heijden, Erik H F M, primary, Carroll, June C, primary, Haugen, Aage, primary, Zienolddiny, Shanbeh, primary, Skaug, Vidar, primary, Wünsch-Filho, Victor, primary, Tajara, Eloiza H, primary, Ayoub Moysés, Raquel, primary, Daumas Nunes, Fabio, primary, Lam, Stephen, primary, Eluf-Neto, Jose, primary, Lacko, Martin, primary, Peters, Wilbert H M, primary, Le Marchand, Loïc, primary, Duell, Eric J, primary, Andrew, Angeline S, primary, Franceschi, Silvia, primary, Schabath, Matthew B, primary, Manjer, Jonas, primary, Arnold, Susanne, primary, Lazarus, Philip, primary, Mukeriya, Anush, primary, Swiatkowska, Beata, primary, Janout, Vladimir, primary, Holcatova, Ivana, primary, Stojsic, Jelena, primary, Mates, Dana, primary, Lissowska, Jolanta, primary, Boccia, Stefania, primary, Lesseur, Corina, primary, Zong, Xuchen, primary, McKay, James D, primary, Brennan, Paul, primary, Amos, Christopher I, primary, and Hung, Rayjean J, primary

Published
2018
Full Text
View/download PDF

40. Prognostic and diagnostic value of serum hyaluronan in patients with pancreatic carcinoma.

Author

Chen, Inna, primary, Dehlendorff, Christian, additional, Johansen, Astrid Zedlitz, additional, Jensen, Benny Vittrup, additional, Krüger, Mie Barthold, additional, Pfeiffer, Per, additional, Bjerregaard, Jon Kroll, additional, Bojesen, Stig Egil, additional, Nielsen, Svend Erik, additional, Hollander, Niels Henrik, additional, Yilmaz, Mette, additional, Rasmussen, Louise Skau, additional, and Johansen, Julia S., additional

Published
2018
Full Text
View/download PDF

41. Dansk Hjerterehabiliteringsdatabase:Strukturelle forhold i 2015 samt opgørelse af patientgrundlag for – og kodeaktivitet i relation til rehabiliteringsydelser opgjort fra Landspatientregistret i 2014

Author

Zwisler, Ann Dorthe Olsen, May, Ole, Prescott, Eva, Eichhorst, Regina, Foghmar, Sussie, Kvist, Birgitte, Christensen, Bo, Gustafsson, Ida, Andersen, Ulla Overgaard, Korsgaard Thomsen, Kristian, Viggers, Lone, Lytken Larsen, Mogens, Hansen, Lene Boye, Bojesen, Stig Egil, Graversen, Hans Peder, Cerqueira, Charlotte, Nakano, Anne, and Rossau, Henriette Knold

Published
2016

42. The prognostic value of serum IL-6 and YKL-40 in patients with metastatic colorectal cancer.

Author

Jensen, Benny Vittrup, primary, Holsey Gramkow, Mathias, additional, Mosgaard, Camilla Stedstrup, additional, Dehlendorff, Christian, additional, Pfeiffer, Per, additional, Qvortrup, Camilla, additional, Yilmaz, Mette K. N., additional, Larsen, Finn Ole, additional, Bojesen, Stig Egil, additional, Schou, Jakob Hagen Vasehus, additional, Boisen, Mogens Karsbol, additional, Nielsen, Dorte, additional, and Johansen, Julia S., additional

Published
2017
Full Text
View/download PDF

43. The prognostic value of serum CA 19-9 in patients with metastatic colorectal cancer.

Author

Mosgaard, Camilla Stedstrup, primary, Holsey Gramkow, Mathias, additional, Dehlendorff, Christian, additional, Nielsen, Dorte, additional, Pfeiffer, Per, additional, Qvortrup, Camilla, additional, Yilmaz, Mette K. N., additional, Larsen, Ole, additional, Bojesen, Stig Egil, additional, Schou, Jakob Vasehus, additional, Boisen, Mogens Karsboel, additional, Johansen, Julia S., additional, and Jensen, Benny Vittrup, additional

Published
2017
Full Text
View/download PDF

44. Mendelian Randomization and mediation analysis of leukocyte telomere length and risk of lung and head and neck cancers.

Author

Kachuri, Linda, Saarela, Olli, Bojesen, Stig Egil, Smith, George Davey, Liu, Geoffrey, Landi, Maria Teresa, Caporaso, Neil E, Christiani, David C, Johansson, Mattias, Panico, Salvatore, Overvad, Kim, Trichopoulou, Antonia, Vineis, Paolo, Scelo, Ghislaine, Zaridze, David, Wu, Xifeng, Albanes, Demetrius, Diergaarde, Brenda, Lagiou, Pagona, and Macfarlane, Gary J

Subjects
HEAD & neck cancer, TELOMERES, MEDIATION, LUNGS, LUNG cancer, CANCER susceptibility
Abstract

Background: Evidence from observational studies of telomere length (TL) has been conflicting regarding its direction of association with cancer risk. We investigated the causal relevance of TL for lung and head and neck cancers using Mendelian Randomization (MR) and mediation analyses.Methods: We developed a novel genetic instrument for TL in chromosome 5p15.33, using variants identified through deep-sequencing, that were genotyped in 2051 cancer-free subjects. Next, we conducted an MR analysis of lung (16 396 cases, 13 013 controls) and head and neck cancer (4415 cases, 5013 controls) using eight genetic instruments for TL. Lastly, the 5p15.33 instrument and distinct 5p15.33 lung cancer risk loci were evaluated using two-sample mediation analysis, to quantify their direct and indirect, telomere-mediated, effects.Results: The multi-allelic 5p15.33 instrument explained 1.49-2.00% of TL variation in our data (p = 2.6 × 10-9). The MR analysis estimated that a 1000 base-pair increase in TL increases risk of lung cancer [odds ratio (OR) = 1.41, 95% confidence interval (CI): 1.20-1.65] and lung adenocarcinoma (OR = 1.92, 95% CI: 1.51-2.22), but not squamous lung carcinoma (OR = 1.04, 95% CI: 0.83-1.29) or head and neck cancers (OR = 0.90, 95% CI: 0.70-1.05). Mediation analysis of the 5p15.33 instrument indicated an absence of direct effects on lung cancer risk (OR = 1.00, 95% CI: 0.95-1.04). Analysis of distinct 5p15.33 susceptibility variants estimated that TL mediates up to 40% of the observed associations with lung cancer risk.Conclusions: Our findings support a causal role for long telomeres in lung cancer aetiology, particularly for adenocarcinoma, and demonstrate that telomere maintenance partially mediates the lung cancer susceptibility conferred by 5p15.33 loci. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

46. Absolute and Relative Risks of Hematologic Disease and Cause-Specific Death in Individuals with Incidentally Discovered Thrombocytopenia: A Prospective Study of Two Independent General Population Cohorts Including 486,782 Individuals from the United Kingdom and Denmark

Author

Juhl, Anne Rudbeck, Glenthoej, Andreas, Nordestgaard, Boerge Groenne, Petersen, Jesper, Dahl, Morten, Ellervik, Christina, Bojesen, Stig Egil, and Helby, Jens

Abstract

Background:

Published
2023
Full Text
View/download PDF

47. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.

Author

Schultz, Nicolai Aagaard, primary, Dehlendorff, Christian, additional, Jensen, Benny Vittrup, additional, Bjerregaard, Jon K., additional, Nielsen, Kaspar, additional, Bojesen, Stig Egil, additional, Calatayud, Dan, additional, Nielsen, Svend Erik, additional, Yilmaz, Mette K. N., additional, Hollander, Niels Henrik, additional, Andersen, Klaus Kaae, additional, and Johansen, Julia S., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results